Axsome Therapeutics (NASDAQ:AXSM) announced its quarterly earnings results on Friday. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02, MarketWatch Earnings reports.
NASDAQ:AXSM traded down $0.05 during trading hours on Friday, reaching $3.87. The company had a trading volume of 448,120 shares, compared to its average volume of 336,109. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $102.91 million, a PE ratio of -3.12 and a beta of -0.51. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $5.95.
A hedge fund recently raised its stake in Axsome Therapeutics stock. Alethea Capital Management LLC lifted its holdings in shares of Axsome Therapeutics Inc (NASDAQ:AXSM) by 102.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 547,443 shares of the company’s stock after buying an additional 276,620 shares during the quarter. Axsome Therapeutics makes up approximately 2.8% of Alethea Capital Management LLC’s investment portfolio, making the stock its 8th largest position. Alethea Capital Management LLC owned approximately 2.09% of Axsome Therapeutics worth $1,889,000 as of its most recent SEC filing. Institutional investors own 16.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Axsome Therapeutics (AXSM) Announces Earnings Results” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://weekherald.com/2018/11/10/axsome-therapeutics-axsm-announces-earnings-results.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.